Maintenance of infliximab treatment in ankylosing spondylitis: Results of a one-year randomized controlled trial comparing systematic versus on-demand treatment
about
TNF-alpha inhibitors for ankylosing spondylitisMethotrexate for ankylosing spondylitisNew era of biologic therapeutics in atopic dermatitisShould axial spondyloarthritis without radiographic changes be treated with anti-TNF agents?Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study.Ankylosing spondylitis patients commencing biologic therapy have high baseline levels of comorbidity: a report from the Australian rheumatology association database.Switching Between Reference Biologics and Biosimilars for the Treatment of Rheumatology, Gastroenterology, and Dermatology Inflammatory Conditions: Considerations for the Clinician.Spondyloarthritides: evolving therapiesInfliximab in ankylosing spondylitis: alone or in combination with methotrexate? A pharmacokinetic comparative studyAntibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseasesInfluence of Immunogenicity on the Efficacy of Long-Term Treatment with TNF α Blockers in Rheumatoid Arthritis and Spondyloarthritis Patients.Influence of methotrexate on infliximab pharmacokinetics and pharmacodynamics in ankylosing spondylitis.Adalimumab successful in sarcoidosis patients with refractory chronic non-infectious uveitis.Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS studyInfliximab dose reduction sustains the clinical treatment effect in active HLAB27 positive ankylosing spondylitis: a two-year pilot study.Developments in the scientific and clinical understanding of the spondyloarthritidesTreating axial and peripheral spondyloarthritis, including psoriatic arthritis, to target: results of a systematic literature search to support an international treat-to-target recommendation in spondyloarthritis.Clinical review: Anti-TNFalpha therapies in uveitis: perspective on 5 years of clinical experience.Anti-TNF-alpha therapy with infliximab in spondyloarthritides.Current therapeutics for spondyloarthritis.Update of the literature review on treatment with biologics as a basis for the first update of the ASAS/EULAR management recommendations of ankylosing spondylitis.Biologic therapies for spondyloarthritis: what is new?Treatment challenges in axial spondylarthritis and future directions.The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases.Immunogenicity of anti-TNFα therapy in psoriasis: a clinical issue?Chronic inflammatory diseases: do immunological patterns drive the choice of biotechnology drugs? A critical review.Step-down strategy of spacing TNF-blocker injections for established rheumatoid arthritis in remission: results of the multicentre non-inferiority randomised open-label controlled trial (STRASS: Spacing of TNF-blocker injections in Rheumatoid ArthriPast, present, and future for biologic intervention in atopic dermatitis.Biologics in spondyloarthritis: TNFα inhibitors and other agents.Analysis of clinical trials of biosimilar infliximab (CT-P13) and comparison against historical clinical studies with the infliximab reference medicinal product.Management of ankylosing spondylitis with infliximab.Therapies of Early, Advanced, and Late Onset Forms of Axial Spondyloarthritis, and the Need for Treat to Target Strategies.Axial Disease in Psoriatic Arthritis study: defining the clinical and radiographic phenotype of psoriatic spondyloarthritis.The effect of comedication with conventional synthetic disease modifying antirheumatic drugs on TNF inhibitor drug survival in patients with ankylosing spondylitis and undifferentiated spondyloarthritis: results from a nationwide prospective study.TNFα blockers followed by continuation of sulfasalazine and methotrexate combination: a retrospective study on cost saving options of treatment in Spondyloarthritis.Axial spondyloarthritis.[German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew's disease and early forms: 8.4 Pharmaceutical therapy, 8.5 Evaluation of therapy success of pharmaceutical measures].The Effect of Comedication With a Conventional Synthetic Disease-Modifying Antirheumatic Drug on Drug Retention and Clinical Effectiveness of Anti-Tumor Necrosis Factor Therapy in Patients With Axial Spondyloarthritis.
P2860
Q24186462-31E53DB4-7D4F-49F4-B7CC-F32DCC5AA01AQ24200564-683C8E21-BB23-4AA5-8B4E-2D355495065BQ27001941-43F86FC6-98F3-4F60-BBD8-705AE9F72DB9Q30239856-57309F30-412C-47F8-9795-87F3F0523DCDQ31085610-8C576E65-F127-4EDC-A41B-87FFDF874DCAQ33602465-D3FB6B45-E367-472C-BA7D-C7B2E63481D1Q33840949-63BD8D4C-88A9-45CE-A39D-60B132BC0581Q34613907-0127D7A0-E640-4113-892F-37BF1E48D091Q35557859-D1BEA676-767F-4FBC-8355-CE76C8481F04Q35557970-1BDFEE46-FF96-4D4F-82C8-A779A5219E02Q35592110-1C26478B-84AB-4C60-AE54-DCFB5B333B83Q35640448-56D7F77E-E456-4EC8-810E-2A8A67CDF08CQ35904466-272C3C18-A7CB-4EAE-BDA2-11B8F8ED5518Q36485893-A2BF5CE9-0928-4C43-8B33-B8581D9BB5C0Q37191464-037E6716-3437-4052-8A9E-AFF9E7CFB5A7Q37207018-AFD20221-B47D-4941-A468-F31496D8C36AQ37465349-B8C0E79F-3C1C-46BB-9E14-03CA07471D5FQ37650221-1D7987B4-FB8B-4265-8038-E3655019214DQ37729028-D7361620-DE95-432A-AE4D-F2E222BCF5A5Q37944297-FB5B4EBD-5C3D-4D8E-8613-4BF7E1EE097CQ37994661-07D6F9F0-833A-4709-A6DD-3141438D10BCQ38031436-333800B3-2119-433C-BAC2-31B90C9E29C7Q38124281-84C58C79-7A38-4AA1-9F18-F99CDFD9265BQ38129037-9A0FB4E9-48AF-4BE8-A749-C069D75A1659Q38150903-38DF6A44-849D-426F-86E5-F1FEE7D95394Q38201788-03ADD10F-95F6-4B4A-B590-0EC8CB25AB0CQ38409321-4460C629-659D-4550-AB61-F3B2EB45B1D2Q38423474-40FDB261-9478-4D3B-8A8B-AB05B5CFB73FQ38522331-CE92FF38-589F-4D0C-A538-2F3AF3DC88E8Q38591275-6BC109B5-41F9-4C55-8780-4F46345872C9Q38993236-0E002DA1-7247-4A9F-B893-1C17EEE816B6Q39135959-C1B1892A-C845-4A2C-9F38-B79647A7A8CAQ41146029-83BB7CF4-A8B7-4276-A6B2-E119C7E72E87Q41359123-4B0990FE-88F1-4A40-94D7-CDA4A7BD3FCBQ48628994-F3CABFDD-8BB1-43D9-9687-E9750489E951Q52870848-0297CCB7-F934-4E03-84E7-BE66610F69A6Q52874129-5CB1AF4C-6959-4111-8EE8-A3304924907CQ53730754-7E313E89-FB33-4433-B2F6-BCDE84861F77
P2860
Maintenance of infliximab treatment in ankylosing spondylitis: Results of a one-year randomized controlled trial comparing systematic versus on-demand treatment
description
wetenschappelijk artikel
@nl
наукова стаття, опублікована у 2007
@uk
name
Maintenance of infliximab trea ...... tic versus on-demand treatment
@en
Maintenance of infliximab trea ...... tic versus on-demand treatment
@nl
type
label
Maintenance of infliximab trea ...... tic versus on-demand treatment
@en
Maintenance of infliximab trea ...... tic versus on-demand treatment
@nl
prefLabel
Maintenance of infliximab trea ...... tic versus on-demand treatment
@en
Maintenance of infliximab trea ...... tic versus on-demand treatment
@nl
P2093
P50
P356
P1476
Maintenance of infliximab trea ...... tic versus on-demand treatment
@en
P2093
Alain Baleydier
Aleth Perdriger
Bernard Combe
Bernard Fournié
Christian Marcelli
Christophe Hudry
Elisabeth Solau-Gervais
Gabriel Baron
Gérard Trape
Isabelle Chary-Valckenaere
P356
10.1002/ART.23167
P577
2007-01-01T00:00:00Z